A Study of Baricitinib (LY3009104) in Healthy Chinese Participants

NCT02758613 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

33

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Baricitinib
DRUG: Placebo

Sponsor

Eli Lilly and Company